Newsroom

Last year CU Innovations’ activities resulted in 145 invention disclosures, 189 patents filed, 41 licensing deals, $375MM of startup financing, and $35MM of gross revenue to the University of Colorado campus having a significant economic impact both in Colorado and nationwide.

Becoming a successful innovator and entrepreneur can be a daunting and difficult process, which is why the University of Colorado Anschutz Medical Campus has developed extensive resources to help its researchers find success in developing novel ways to help others. With hopes of inspiring faculty and offering tangible advice, the CU Department of Medicine highlighted these resources during its latest Research Achievement Highlights (REACH) forum through presentations by two experts: V. Michael Holers, MD, and Gali Baler, PhD.

Q32 Bio Inc., a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, announced the completion of its merger with Homology Medicines, Inc. ("Homology").

Q32 Bio Inc. announced the publication of preclinical data in Molecular Therapy that further validates the therapeutic potential of ADX-097, a tissue-targeted complement inhibitor.

Innovaccer Inc. today announced that it has acquired a 100% stake in Cured, a leading digital marketing and CRM platform for healthcare. This strategic move marks a significant milestone in Innovaccer’s commitment to revolutionize healthcare.

Vita Health, the first provider of clinically validated suicide prevention through innovative care management, announced today the close of a $22.5M Series A funding round.

In this episode of the CU Anschutz 360 podcast, Daniel LaBarbera, PhD, director of the Center for Drug Discovery, talks about harnessing technology and innovation to speed the development of new therapies.

Reimagine Care and CU Innovations announce a poster presentation at the prestigious 2023 American Society of Hematology (ASH) Annual Meeting and Exposition.